Cellular-based immunotherapies for patients with glioblastoma multiforme. - Wikidata - awgldk - TriplyDB

Cellular-based immunotherapies for patients with glioblastoma multiforme.

Cellular-based immunotherapies for patients with glioblastoma multiforme.

http://www.wikidata.org/entity/Q35821404

about

Dendritic cell-based immunotherapy for glioma: multiple regimens and implications in clinical trials Clinical efficacy of tumor antigen-pulsed DC treatment for high-grade glioma patients: evidence from a meta-analysis Dendritic Cell-Based Immunotherapy Treatment for Glioblastoma Multiforme Natural killer (NK) cells inhibit systemic metastasis of glioblastoma cells and have therapeutic effects against glioblastomas in the brain.The Effect of Vector Silencing during Picornavirus Vaccination against Experimental Melanoma and Glioma Dendritic cell immunotherapy versus bevacizumab plus irinotecan in recurrent malignant glioma patients: a survival gain analysis.Glioblastoma multiforme: State of the art and future therapeutics.Dendritic cell vaccination for glioblastoma multiforme: review with focus on predictive factors for treatment response.Interstitial chemotherapy for malignant glioma: Future prospects in the era of multimodal therapy

P2860

Q27014829-BD55F32D-EFB2-43AF-937D-0AB1AC0C055E Q27348437-44DA0383-B82A-47C0-935F-466FDE043966 Q28087485-68018845-E8E2-402F-B5DB-FC1107230B14 Q35878535-3705ACFD-8208-4D21-A6FB-56C6CBDE172A Q36112877-3B1B2776-C6E5-48B0-B55A-3AEC974150F5 Q36201736-A2577715-1D6F-44C1-A0D6-41E3668EB72B Q38225874-38272CA3-10F0-4612-9BF2-420F8B0019DB Q38912265-8887F7CF-FADA-4D1A-933C-76513C091432 Q39034877-3D45ABDB-8D96-483C-9A56-6692B6BC5CBC

P2860

Cellular-based immunotherapies for patients with glioblastoma multiforme.

http://www.wikidata.org/entity/Q35821404

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Cellular-based immunotherapies for patients with glioblastoma multiforme.

@ast

Cellular-based immunotherapies for patients with glioblastoma multiforme.

@en

type

label

Cellular-based immunotherapies for patients with glioblastoma multiforme.

@ast

Cellular-based immunotherapies for patients with glioblastoma multiforme.

@en

prefLabel

Cellular-based immunotherapies for patients with glioblastoma multiforme.

@ast

Cellular-based immunotherapies for patients with glioblastoma multiforme.

@en

P1433

Q35821404-582DA79F-6D38-4957-ABED-B94D494AA2EC

P1476

Q35821404-40E30876-44EA-4B00-B9D3-D37BF62C7FCC

P2093

Q35821404-B2936E90-6E36-4025-B556-757A63CB043D

Q35821404-E1927C7B-E812-40BB-B950-13D411439003

P275

Q35821404-EFF63D81-D332-47D8-8023-3CB1A46DC876

P2860

Q35821404-0860DE5C-3AE3-4205-A66A-FD8B509BB270

Q35821404-093A91C0-FC71-4E98-9E5C-09AA2F7F2B11

Q35821404-0A8DA80D-D7A0-4AD4-BFB8-7FD3EA56C3F8

Q35821404-1069A36F-39AF-4C98-953D-699288C66586

Q35821404-109C6AAC-F041-4976-B550-617A9102123D

Q35821404-10BBB1FC-1BF4-41E3-9368-0F900F895267

Q35821404-10EAC079-8134-484A-99E4-8C38FAEC5C8C

Q35821404-15E59299-87F8-4DF5-A2D4-BF7C1986C505

Q35821404-185EB4BA-1DE6-4944-BD2D-8AD52BA58F39

Q35821404-1A8421AC-5D2D-4A54-8ED3-68B083E5C6AC

P304

Q35821404-ED742939-DDF9-41C1-95C9-CB69DCF87FE1

P31

Q35821404-81FC040F-1614-4D73-8A42-578D3343B40E

P356

Q35821404-58B800F9-D901-4768-A505-690DC36BF2AC

P478

Q35821404-C0C8ED14-E7B4-42C2-890B-EF20615AE26D

P50

Q35821404-BA3FC71A-FF97-42D9-A3CD-6B3BE288592D

P5008

Q35821404-086F9332-2933-4465-AF2E-7F095E35AB3C

P577

Q35821404-05A4C628-D174-4AC1-AD1E-EBD34178F234

P5875

Q35821404-98D29949-0F96-4F8E-9911-06B88A410E54

P698

Q35821404-70D4831C-BE1E-4E68-9E08-1EC7D2E48005

P921

Q35821404-F94FD5BE-F0F9-4A05-8B92-CA9D58255BDA

Q35821404-FC9C39BC-B9FB-48EB-8C14-912D26CD82AB

Q35821404-FFF2959C-9CFB-4E15-91F5-E389ACCD6949

P932

Q35821404-38040C45-7EDF-4022-B281-379B2F94BC8F

P356

P1433

Clinical and Developmental Immunology

P1476

Cellular-based immunotherapies for patients with glioblastoma multiforme

@en

P2093

Michael Schmitt

http://www.w3.org/2001/XMLSchema#string

Xun Xu

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 3.0 Unported

P2860

Tumor-specific Th17-polarized cells eradicate large established melanoma

MGMT gene silencing and benefit from temozolomide in glioblastoma.

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Identification of a cancer stem cell in human brain tumors

The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas

A function for interleukin 2 in Foxp3-expressing regulatory T cells

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Immunobiology of dendritic cells

Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma

P304

764213

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2012/764213

http://www.w3.org/2001/XMLSchema#string

P478

2012

http://www.w3.org/2001/XMLSchema#string

P50

Florian Stockhammer

P5008

P577

2012-02-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

223986936

http://www.w3.org/2001/XMLSchema#string

P698

22474481

http://www.w3.org/2001/XMLSchema#string

P921

P932

3299309

http://www.w3.org/2001/XMLSchema#string